why choose us

First received: May 17, 2023

Clinical Trial: An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

Study Status: Completed

Recruit Status: RECRUITING

Condition: Breast Cancer, Early Breast Cancer

Study Type: INTERVENTIONAL


Official Title: CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine The

Brief Summary: This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy).The planned duration of treatment in either arm within the study will be 7 years.

Read more